{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273269","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.527586+00:00","generated_at":"2026-05-16T22:32:28.983728+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lyell acquires exclusive global rights to CAR T candidate LYL273 for mCRC; Phase 1 shows 67% ORR at highest dose","bullets":["Upfront $40M cash + 1.9M Lyell shares; up to $820M in milestones plus tiered royalties up to 10% on US net sales.","Phase 1 at Dose Level 2 (2x10^6 cells/kg): 67% overall response rate (4/6), 83% disease control rate, median PFS 7.8 months.","Safety includes CRS (83% Grade 1-2), diarrhea (83% managed with prophylaxis), one Grade 5 event; Fast Track designated by FDA.","Lyell expects cash to fund into 2027; 2025 net cash use guided to $155-160M (excl. $40M), below prior $175-185M.","Investor webcast at 8:30 AM ET; next data update expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273269","json":"https://secwatch.observer/filing/0001193125-25-273269.json","markdown":"https://secwatch.observer/filing/0001193125-25-273269.md","text":"https://secwatch.observer/filing/0001193125-25-273269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525273269/0001193125-25-273269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525273269/d57756d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:32:28.983728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}